Drugs on the horizon for diabesity

Clifford J. Bailey

Drugs on the horizon for diabesity

Clifford J. Bailey^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Abstract

The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ("dual PPARs"), and the CBI cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.

Original language	English
Pages (from-to)	353-359
Number of pages	7
Journal	Current Diabetes Reports
Volume	5
Issue number	5
Publication status	Published - 1 Oct 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{6508f1b29a334fc79964cda81d04a892,

title = "Drugs on the horizon for diabesity",

abstract = "The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ({"}dual PPARs{"}), and the CBI cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.",

author = "Bailey, \{Clifford J.\}",

year = "2005",

month = oct,

day = "1",

language = "English",

volume = "5",

pages = "353--359",

journal = "Current Diabetes Reports",

issn = "1534-4827",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Drugs on the horizon for diabesity

AU - Bailey, Clifford J.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ("dual PPARs"), and the CBI cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.

AB - The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ("dual PPARs"), and the CBI cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.

UR - https://www.scopus.com/pages/publications/27744583196

UR - https://link.springer.com/article/10.1007%2Fs11892-005-0093-1

M3 - Article

C2 - 16188170

AN - SCOPUS:27744583196

SN - 1534-4827

VL - 5

SP - 353

EP - 359

JO - Current Diabetes Reports

JF - Current Diabetes Reports

IS - 5

ER -

Drugs on the horizon for diabesity

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this